After more than 500,000 deaths and nearly a full year, experts say there are a growing number of reasons to be optimistic about the direction of the pandemic. Cases, hospitalizations and deaths have all fallen dramatically in recent weeks.
Among those falling numbers, a vaccine from Johnson & Johnson that may be authorized by the Food and Drug Administration this week. Dr. Ashish Jha of Brown University explains why the shot is just as desirable as already-authorized vaccines from Pzifer and Moderna.
The Biden administration has promised to ramp up vaccination efforts even more as soon as Congress authorizes more money to do so. NPR congressional correspondent Kelsey Snell has an update on the $1.9 trillion rescue package speeding through the House.
Additional reporting on the drop in COVID-19 case rates in this episode came from NPR's Allison Aubrey and Will Stone.
